Incyte Corp
$
73.96
-0.36 (-0.48%)
| Volume: | 1,689,855 | Avg Vol (1m): | 1,206,618 |
| Market Cap $: | 15.85 Bil | Enterprise Value $: | 14.44 Bil |
| P/E (TTM): | 145.02 | P/B: | 8.19 |
| Earnings Power Value | 7.54 |
| Net Current Asset Value | 5.22 |
| Tangible Book | 7.29 |
| Projected FCF | 10.69 |
| Median P/S Value | 169.51 |
| Graham Number | 9.15 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 9/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 39.81 | ||
| Equity-to-Asset | 0.73 | ||
| Debt-to-Equity | 0.02 | ||
| Debt-to-EBITDA | 0.21 | ||
| Interest Coverage | 100.73 | ||
| Piotroski F-Score | 7 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 13.71 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | -2.72 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 29.49%
WACC 10.48%
| ||
Profitability & Growth : 7/10
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 8.26 | ||
| Net Margin % | 5.82 | ||
| ROE % | 6.28 | ||
| ROA % | 4.50 | ||
| ROC (Joel Greenblatt) % | 40.27 | ||
| 3-Year Total Revenue Growth Rate | 35.70 | ||
| 3-Year Total EBITDA Growth Rate | 20.60 | ||
| 3-Year EPS w/o NRI Growth Rate | 157.10 |
» INCY's 30-Y Financials
Financials (Next Earnings Date: 2019-04-30)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:INCY
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 541714   SIC : 8731 |
| Compare | OCSE:GEN OCSE:NZYM B NAS:NKTR XBRU:UCB NAS:BMRN NAS:BIVV HKSE:02269 NAS:JUNO NAS:ALNY NAS:BGNE NAS:JAZZ XMCE:GRF.P NAS:BLUE HKSE:01177 NAS:SGEN NAS:AVXS NAS:NBIX NAS:ALKS NAS:SAGE NAS:EXEL |
| Traded in other countries | ICY.Germany 0J9P.UK |
| Address | 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803 |
| Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which is licensed by Eli Lilly, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including IDO inhibitor epacadostat and next-generation JAK inhibitor itacitinib. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 145.02 | ||
| Forward PE Ratio | 38.91 | N/A | |
| PE Ratio without NRI | 145.02 | ||
| Price-to-Owner-Earnings | 267.00 | ||
| PB Ratio | 8.19 | ||
| PS Ratio | 8.44 | ||
| Price-to-Free-Cash-Flow | 60.77 | ||
| Price-to-Operating-Cash-Flow | 47.44 | ||
| EV-to-EBIT | 123.58 | ||
| EV-to-EBITDA | 84.05 | ||
| EV-to-Revenue | 7.68 | ||
| Current Ratio | 4.31 | ||
| Quick Ratio | 4.29 | ||
| Days Inventory | 23.23 | ||
| Days Sales Outstanding | 59.66 | ||
| Days Payable | 402.73 |
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -4.50 |
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 10.14 | ||
| Price-to-Projected-FCF | 6.92 | ||
| Price-to-Median-PS-Value | 0.44 | ||
| Price-to-Graham-Number | 8.08 | ||
| Earnings Yield (Joel Greenblatt) % | 0.81 |
More Statistics
| Revenue (TTM) (Mil) $ | 1,881.88 |
| EPS (TTM) $ | 0.51 |
| Beta | 1.32 |
| Volatility % | 43.37 |
| 52-Week Range $ | 57 - 88.83 |
| Shares Outstanding (Mil) | 214.26 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 7 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | N |